Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Berzofsky Website

Jay A. Berzofsky, M.D., Ph.D.

Selected Publications

1)  Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y, Gagnon S, Belyakov IM, Mumper RJ, Berzofsky JA.
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.
Nat. Med. 18: 1291-1296., 2012.
[Journal]
2)  O'Konek JJ, Illarionov P, Khursigara DS, Ambrosino E, Izhak L, Castillo BF, Raju R, Khalili M, Kim H, Howell AR, Besra GS, Porcelli SA, Berzofsky JA, Terabe M.
Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity.
J. Clin. Invest. 121: 683-94, 2011.
[Journal]
3)  Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA.
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.
J. Clin. Invest. 120: 607-16, 2010.
[Journal]
4)  Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, Xia Z, Venzon D, Berzofsky JA, Terabe M.
Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity.
Cancer Res. 73: 1514-23, 2013.
[Journal]
5)  Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA.
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.
Proc. Natl. Acad. Sci. U.S.A. 107: 9843-8, 2010.
[Journal]
6)  O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA.
ß-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.
Clin. Cancer Res. 19: 4404-11, 2013.
[Journal]
7)  Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA.
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
Clin. Cancer Res. 15: 6560-9, 2009.
[Journal]
8)  Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R, Terabe M, Sui Y, Berzofsky JA.
IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses.
J. Leukoc. Biol. 90: 205-14, 2011.
[Journal]
9)  Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA.
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 5201-6, 2008.
[Journal]
10)  Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA.
Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines.
Proc. Natl. Acad. Sci. U.S.A. 105: 16260-5, 2008.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 11/21/2013.